Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19193029 | 0.88 | KDM2B (0.33) | KDM2BL3MBTL3HRH3HTR6 | |
| SCHEMBL28002021 | 0.85 | KDM2B (0.34) | KDM2BL3MBTL3 | |
| SCHEMBL147003 | 0.85 | SLC6A4 (0.35) | KDM2BL3MBTL3HTR6 | |
| SCHEMBL151490 | 0.83 | SLC6A4 (0.37) | KDM2BL3MBTL3HTR6 | |
| SCHEMBL149070 | 0.83 | SLC6A4 (0.37) | KDM2BL3MBTL3HTR6 | |
| SCHEMBL9047777 | 0.83 | KDM2B (0.39) | KDM2BL3MBTL3 | |
| SCHEMBL6636518 | 0.83 | KDM2B (0.39) | KDM2BL3MBTL3 | |
| SCHEMBL9045610 | 0.83 | KDM2B (0.39) | KDM2BL3MBTL3 | |
| SCHEMBL31610339 | 0.79 | KDM2B (0.39) | KDM2BL3MBTL3 | |
| SCHEMBL20096220 | 0.78 | HRH3 (0.44) | KDM2BL3MBTL3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | KDM2B 2367/4885L3MBTL3 4163/4885HRH3 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.